Biomarker Testing (US)
Genentech Leverages Social Media to Raise Awareness About Biomarker Testing with Patient Stories
Genentech is utilizing Facebook and TikTok to spread awareness about the importance of biomarker testing in lung cancer patients. Through a series of videos featuring patients with ALK-positive non-small cell lung cancer (NSCLC), the company emphasizes the significance of “Asking About ALK.”
As a leading provider of Alecensa, a targeted treatment for ALK-positive NSCLC, Genentech recognizes the crucial role biomarker testing plays in identifying patients who may benefit from this therapy. Research has shown that patients with ALK-positive lung cancer have improved outcomes with Alecensa, with a significant proportion remaining alive after five years.
Despite the potential benefits of biomarker testing, many cancer patients remain unaware of its importance. A recent survey revealed that only 49% of cancer patients were tested for biomarkers, and fewer than 1 in 7 patients proactively requested the test. Genentech aims to empower patients to advocate for themselves and ensure they receive appropriate testing.
The company’s social media campaign features videos of young people who were diagnosed with NSCLC and have benefited from biomarker testing. These patients share their personal stories, emphasizing the importance of early detection and targeted treatment.